Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Michael Sargent Binkley, Jamie E Flerlage, Kerry J Savage, Saad Akhtar, Raphael Steiner, Xiao-Yin Zhang, Michael Dickinson, Anca Prica, Ajay Major, Peter G Hendrickson, David Hopkins, Andrea Ng, Carla Casulo, Jonathan Baron, Kenneth B Roberts, Jalila Al Kendi, Alex Balogh, Umberto Ricardi, Pallawi Torka, Lena Specht, Ravindu De Silva, Keir Pickard, Lindsay J Blazin, Michael Henry, Christine M Smith, Daniel Halperin, Jessica Brady, Bernadette Brennan, Maria Anatolevna Senchenko, Marie Reeves, Bradford S Hoppe, Stephanie Terezakis, Dipti Talaulikar, Marco Picardi, Youlia Kirova, Paige Fergusson, Eliza A Hawkes, Denise Lee, Nicole Wong Doo, Allison Barraclough, Chan Y Cheah, Matthew Ku, Nada Hamad, Howard Mutsando, Michael Gilbertson, Tamara Marconi, Nicholas Viiala, Matthew J Maurer, Dennis A Eichenauer, Richard T Hoppe
PURPOSE: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of pediatric and adult patients with NLPHL. METHODS: Thirty-eight institutions participated in the Global nLPHL One Working Group retrospective study of NLPHL cases from 1992 to 2021. We measured progression-free survival (PFS), overall survival (OS), transformation rate, and lymphoma-specific death rate...
March 26, 2024: Journal of Clinical Oncology
#2
JOURNAL ARTICLE
Mutsumi Koyama, Euido Nishijima, Takaya Honda, Chizuru Gonmori-Ohta, Takeaki Sasamoto, Katsuyuki Tanaka, Akira Watanabe, Tadashi Nakano, Masaharu Akiyama
BACKGROUND: Ocular manifestations are known for non-Hodgkin lymphoma, but are rare for Hodgkin lymphoma. We report a case of Vogt-Koyanagi-Harada (VKH) disease presenting as serous retinal detachment and uveitis in both eyes in a child undergoing chemotherapy for Hodgkin lymphoma. CASE PRESENTATION: The patient was a 7-year-old boy with stage IIB Hodgkin lymphoma (nodular lymphocyte predominant type) who was undergoing chemotherapy, including 2 cycles of the OEPA regimen and 1 cycle of the COPDAC regimen...
March 13, 2024: BMC Ophthalmology
#3
JOURNAL ARTICLE
M A Senchenko, D M Konovalov
BACKGROUND: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) consist of lymphocyte predominant cell or LP-cell. Despite their origin from active germinal centers, in some cases LP-cells express IgD, which is characteristic of naive B-lymphocytes of the mantle zone. Due to the rarity of NLPHL, assessing the frequency of IgD-positive cases is difficult. This marker can serve not only for differential diagnosis with other diseases, but also indicate the possible heterogeneity of NLPHL, which is currently represented by six immunoarchitectural patterns...
2024: Arkhiv Patologii
#4
JOURNAL ARTICLE
Makka Adam, Yonas Bekuretsion, Amha Gebremedhin, Anna Kwiecinska, Rawleigh Howe, Beyene Petros, Mats Jerkeman
Epstein Barr Virus (EBV) has been recognized for its ability to transform B lymphocytes and for its association with different types of cancers including Hodgkin lymphoma. In addition, EBV may also modulate the microenvironment of HL. In this study, we aimed to investigate the prevalence of EBV among HL cases in Ethiopia and to assess the tissue cellular composition of EBV-related and EBV-unrelated cases. We constructed a tissue microarray (TMA) of 126 consecutive cases of classical HL (CHL) and nodular lymphocyte predominant HL (NLPHL) from a tertiary cancer centre, Tikur Anbessa Hospital, Addis Ababa, Ethiopia, and evaluated a panel of immunohistochemical markers...
2023: Journal of Clinical and Experimental Hematopathology: JCEH
#5
REVIEW
Min En Nga
Background Fine needle aspiration cytology (FNAC) is an accurate, minimally invasive and cost-effective biopsy method for enlarged lymph nodes. While the role of lymph node FNAC in the diagnosis of infectious or reactive conditions and metastatic malignancy is unquestioned, differing views still exist on its role in the diagnosis of lymphoma. Nevertheless, regardless of the practice setting, pitfalls and potential for error exist, and it is incumbent upon the pathologist to be aware of these pitfalls; as this is the first line of defence against errors...
December 20, 2023: Acta Cytologica
#6
JOURNAL ARTICLE
Siba El Hussein, Hong Fang, Fatima Zahra Jelloul, Wei Wang, Sanam Loghavi, Roberto N Miranda, Jonathan W Friedberg, W Richard Burack, Andrew G Evans, Jie Xu, L Jeffrey Medeiros
CONTEXT.—: It is known that a subset of cases of classic Hodgkin lymphoma (CHL) with B-cell-rich nodules (lymphocyte-rich CHL) exhibits morphologic and immunophenotypic features that overlap with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), raising diagnostic difficulties that can be resolved in most cases by performing an adequate battery of immunohistochemical studies. OBJECTIVE.—: To fully characterize cases of T-cell-rich Hodgkin lymphoma where a specific diagnosis of NLPHL (ie, pattern D) or CHL could not be made even after complete immunophenotypic investigation...
December 7, 2023: Archives of Pathology & Laboratory Medicine
#7
REVIEW
Christian Steidl, Robert Kridel, Michael Binkley, Lindsay M Morton, Amy Chadburn
Lymphoid cancers are among the most frequent cancers diagnosed in adolescents and young adults (AYA), ranging from approximately 30%-35% of cancer diagnoses in adolescent patients (age 10-19) to approximately 10% in patients aged 30-39 years. Moreover, the specific distribution of lymphoid cancer types varies by age with substantial shifts in the subtype distributions between pediatric, AYA, adult, and older adult patients. Currently, biology studies specific to AYA lymphomas are rare and therefore insight into age-related pathogenesis is incomplete...
November 2023: EJHaem
#8
JOURNAL ARTICLE
Jonathan Weiss, Kathryn Gibbons, Vida Ehyaee, Vanessa Perez-Silos, Alejandro Zevallos, Mark Maienschein-Cline, Eileen Brister, Maria Sverdlov, Eshana Shah, Jayalakshmi Balakrishna, Emily Symes, John K Frederiksen, Peter H Gann, Robert Post, Nicolas Lopez-Hisijos, John Reneau, Girish Venkataraman, Nathanael Bailey, Noah A Brown, Mina L Xu, Ryan A Wilcox, Kedar Inamdar, Carlos Murga-Zamalloa
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare and relatively indolent B-cell lymphoma. Characteristically, the (LP-cells) tumor cells are embedded in a microenvironment enriched in lymphocytes. More aggressive variants of mature B cell and peripheral T cell lymphomas exhibit nuclear expression of the Polo-Like Kinase 1 (PLK1) protein, stabilizing c-MYC and associated with worse clinical outcomes. We demonstrate frequent expression of PLK1 in the LP-cells in NLPHL cases (100%, n = 76). In contrast, less than 5% of classical Hodgkin lymphoma cases (n = 70) show PLK1 expression within the tumor cells...
November 1, 2023: American Journal of Pathology
#9
JOURNAL ARTICLE
Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Rare Lymphoma with Isolated Hepatic Presentation.
Bruno David Freitas, Andreia Salgadinho Machado, Margarida Lagarto, Inês Araújo, Candida Fonseca
UNLABELLED: Primary hepatic lymphoma (PHL) is extremely rare, accounting for less than 1% of all lymphomas, and is limited to the liver without extrahepatic involvement. A 30-year-old male was admitted in the Emergency Department complaining of weakness, fever, night sweats, significant weight loss, discrete ring alopecia, hepatomegaly, right axillary adenopathy and oedema of both legs. Laboratory evaluation showed normocytic normochromic anaemia, thrombocytosis, hyperbilirubinemia, cholestasis and increased international normalised ratio (INR)...
2023: European Journal of Case Reports in Internal Medicine
#10
JOURNAL ARTICLE
Luisa Lorenzi, Silvia Lonardi, Michela Bonezzi, Stefania Zini, Mattia Bugatti, Arianna Valzelli, Flavia Melotti, Mattia Facchetti, Iacopo Ghini, Vincenzo Villanacci, Piera Balzarini, Marco Pizzi, Viviana Giustini, Anna Galvagni, Marco Chiarini, Angelo Paolo Dei Tos, William Vermi, Stefano Casola, Fabio Facchetti
Evaluation of B-cell clonality can be challenging in the interpretation of lymphoid infiltrates on tissue sections. Clonality testing based on IG gene rearrangements analysis by PCR (IG-PCR) is the gold standard. Alternatively, B-cell clonality can be assessed by the recognition of immunoglobulin light chain (IgLC) restriction, by immunohistochemistry (IHC), chromogenic in situ hybridization (ISH) or flow cytometry (FC). IG-PCR requires molecular facilities, and FC requires cell suspensions, both not widely available in routine pathology units...
October 26, 2023: Virchows Archiv: An International Journal of Pathology
#11
JOURNAL ARTICLE
Christos Panayi, Ayse U Akarca, Alan D Ramsay, Ananth G Shankar, Brunangelo Falini, Miguel A Piris, David Linch, Teresa Marafioti
BACKGROUND: The clinicopathological spectrum of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), also known as nodular lymphocyte predominant B-cell lymphoma, partially overlaps with T-cell/histiocyte-rich large B-cell lymphoma (THRLCBL). NLPHL histology may vary in architecture and B-cell/T-cell composition of the tumour microenvironment. However, the immune cell phenotypes accompanying different histological patterns remain poorly characterised. METHODS: We applied a multiplexed immunofluorescence workflow to identify differential expansion/depletion of multiple microenvironmental immune cell phenotypes between cases of NLPHL showing different histological patterns (as described by Fan et al, 2003) and cases of THRLBCL...
2023: Frontiers in Oncology
#12
JOURNAL ARTICLE
N J Park, S M Hiniker, H H Guo, R H Advani, R T Hoppe, M S Binkley
PURPOSE/OBJECTIVE(S): There is no standard treatment for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Although response by positron emission tomography (PET) for classic Hodgkin lymphoma (cHL) has allowed for response-adapted treatment, similar approaches for NLPHL have not been developed. This is in part due to the lack of data for PET response to treatment. Therefore, we sought to investigate PET responses to management for NLPHL. MATERIALS/METHODS: We retrospectively identified 47 patients who were diagnosed with or treated for NLPHL between 2001-2018 at a single institution and underwent a staging PET...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
#13
JOURNAL ARTICLE
S Narula, P Hoskin
PURPOSE/OBJECTIVE(S): Involved site radiotherapy as a single modality is considered standard of care for early-stage non-bulky nodular lymphocyte predominant Hodgkin's Lymphoma (NLPHL) with excellent rates of local control and overall survival. Guidelines suggest a dose of 30 Gy in conventional fractionation, however NLPHL has an indolent course and clinically behaves likes a low-grade lymphoma. Given the good prognosis NLPHL has been treated as low grade non-Hodgkin's lymphoma with a dose of 24 Gy in 12 fractions...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
#14
Yaser Rahim, Michael Maroules, Edwin Teehan, Ghassan Bassil, Vanessa Boosahda
In this report, we present the case of a patient with an uncommon triple diagnosis of (1) follicular (nodular) lymphoma, (2) nodular lymphocyte predominant Hodgkin lymphoma, and (3) diffuse large B-cell lymphoma non-germinal center B-cell (non-GCB) subtype. Although transformation of follicular lymphoma and nodular lymphocyte predominant lymphoma to more aggressive forms such as diffuse large B-cell lymphoma is possible; it generally happens many years after diagnosis. Moreover, there have been reported cases of follicular lymphoma with transformation and nodular lymphocyte predominant Hodgkin lymphoma with transformation at the time of diagnosis, but it is very uncommon to see all three present on initial diagnosis...
August 2023: Curēus
#15
Muzamil Khan, Khalil Diab
Endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA) has proven to be highly accurate in lung cancer diagnosis and staging. However, its efficacy in diagnosing lymphoma, especially Hodgkin's lymphoma, remains controversial, mainly due to the need for larger biopsies for definitive diagnosis. This case study presents a 53-year-old HIV-positive man with a controlled viral load, who presented with a large left hilar mass and a left upper lobe nodule, both showing significant uptake on positron emission tomography scans...
August 2023: Curēus
#16
JOURNAL ARTICLE
Nesreen Ali, Emad Moussa, Eman Khorshed, Mohamed S Zaghloul, Amr Elnashar, Amr Abdalla
BACKGROUND: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), recently known as nodular lymphocyte-predominant B-cell lymphoma (NLPBL), accounts for 5%-10% of Hodgkin lymphoma (HL). Different morphologic patterns of NLPBL are identified and categorized as typical patterns (type A and B) and variant histologic patterns (types C, D, E, and F). PATIENTS AND METHOD: We investigated different morphologic patterns, CD30 and IgD expression in pediatric patients with NLPBL diagnosed at the Children's Cancer Hospital Egypt...
August 28, 2023: Pediatric Blood & Cancer
#17
JOURNAL ARTICLE
Sergej Sereda, Ananth G Shankar, Luise Weber, Alan D Ramsay, Georgina W Hall, Janis Hayward, William Hamish Beith Wallace, Judith Landman-Parker, Andreas Braeuninger, Dirk Hasenclever, Astrid Schneider, Christine Mauz-Koerholz, Dieter Körholz, Stefan Gattenloehner
Early-stage pediatric nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) can be treated effectively with low-intensity chemotherapy, most frequently cyclophosphamide in combination with vinblastine and prednisone (CVP). Descriptive histological risk factors based on the disease-defining lymphocyte predominant cells (LP cells) as used within the Fan classification, are less predictive in early-stage patients. We used deep learning-based cell detection and spatial analysis on digitized biopsy slides from 53 early-stage pediatric NLPHL patients to quantitatively assess LP cell histomorphometry...
August 23, 2023: Blood Advances
#18
REVIEW
Sylvia Hartmann, Stefan Dojcinov, Snjezana Dotlic, Sarah E Gibson, Eric D Hsi, Wolfram Klapper, Monika Klimkowska, Socorro Maria Rodriguez Pinilla, Julia Richter, Elena Sabattini, Thomas Tousseyn, Daphne de Jong
Session 4 of the 2021 European Association of Haematopathology/Society for Hematopathology Workshop focused on nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). First, the spectrum of immunophenotypic variations in NLPHL and the defining criteria for classic Hodgkin Lymphoma (CHL) were discussed. The added value of further immunophenotypic characterization of both tumor cells and microenvironment to support the differential diagnosis was presented. Next, unusual cases with combined growth patterns and evolution of morphological features over time were presented to explore the clinicopathological impact of presumed high-risk patterns...
August 2, 2023: Virchows Archiv: An International Journal of Pathology
#19
REVIEW
Feras Ally, David Gajzer, Jonathan R Fromm
Classic Hodgkin lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, and T cell/histiocyte-rich large B cell lymphoma form a unique set of lymphomas with similar morphologic growth patterns (occasional neoplastic cells within a prominent cellular cell background) that are pathobiologically related. Distinguishing these entities has been historically difficult by flow cytometry; however, our laboratory has developed antibody-fluorochrome combinations capable of immunophenotyping these lymphomas. Additionally, characterization of the background reactive lymphocytes can aid in narrowing the differential diagnosis...
September 2023: Clinics in Laboratory Medicine
#20
JOURNAL ARTICLE
Hervé Ghesquières
DIAGNOSIS AND STAGING OF HODGKIN LYMPHOMA. Hodgkin lymphoma (HL) is composed of two distinct disease entities: classical HL (cHL) and nodular lymphocyte predominant HL (NLPHL). NLPHL is a rare entity with a specific therapeutic management. The subgroups of cHL are nodular sclerosis, mixed cellularity, lymphocyte depletion and lymphocyte-rich HL. The initial diagnosis of HL is made by a biopsy to analyze with accuracy the architecture of the lymph node. Most HL patients present with supradiaphragmatic lymphadenopathy...
June 2023: La Revue du Praticien
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
